Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Single-Center Study Evaluating Absolute Bioavailability, Safety and Tolerability of Subcutaneous Formulation of RYI-018 Compared to Intravenous Formulation in Overweight and Obese Healthy Volunteers

Trial Profile

A Phase 1, Open-Label, Single-Center Study Evaluating Absolute Bioavailability, Safety and Tolerability of Subcutaneous Formulation of RYI-018 Compared to Intravenous Formulation in Overweight and Obese Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2018

At a glance

  • Drugs Namacimab (Primary) ; Namacimab
  • Indications Diabetic nephropathies; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Focus Pharmacokinetics
  • Sponsors Bird Rock Bio
  • Most Recent Events

    • 19 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 19 Nov 2018 Recruitment completion is expected on 22 Nov 2018 according to Australian New Zealand Clinical Trials Registry.
    • 22 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top